Phase II Study of JR-141 in Patients With Mucopolysaccharidosis II
Latest Information Update: 22 Feb 2022
At a glance
- Drugs Pabinafusp alfa (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions
- Sponsors JCR Pharmaceuticals
- 15 Feb 2022 Results published in the JCR Pharmaceuticals Media Release.
- 15 Feb 2022 According to a JCR Pharmaceuticals media release, data from this trial was presented at the at the 18th Annual WORLDSymposium.
- 16 Feb 2021 According to a JCR Pharmaceuticals media release, data from this and NCT03568175 were presented at the at the 17th Annual WORLDSymposium™2021.